The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors by Gesmundo, Iacopo et al.
June 2016 | Volume 7 | Article 661
Original research
published: 16 June 2016
doi: 10.3389/fendo.2016.00066
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Pierrette Gaudreau, 
Centre hospitalier de l’Université 
de Montréal, Canada
Reviewed by: 
Gábor B. Makara, 
Hungarian Academy of Sciences, 
Hungary  
Benno Roozendaal, 
Radboud University Nijmegen 
Medical Centre, Netherlands
*Correspondence:
Riccarda Granata  
riccarda.granata@unito.it
Specialty section: 
This article was submitted to 
Neuroendocrine Science, 
a section of the journal 
Frontiers in Endocrinology
Received: 15 April 2016
Accepted: 01 June 2016
Published: 16 June 2016
Citation: 
Gesmundo I, Villanova T, 
Gargantini E, Arvat E, Ghigo E and 
Granata R (2016) The 
Mineralocorticoid Agonist 
Fludrocortisone Promotes Survival 
and Proliferation of Adult 
Hippocampal Progenitors. 
Front. Endocrinol. 7:66. 
doi: 10.3389/fendo.2016.00066
The Mineralocorticoid agonist 
Fludrocortisone Promotes survival
and Proliferation of adult 
hippocampal Progenitors
 
Iacopo Gesmundo1, 2, Tania Villanova1,2, Eleonora Gargantini1, 2, Emanuela Arvat3,  
Ezio Ghigo2 and Riccarda Granata1,2*
1 Laboratory of Molecular and Cellular Endocrinology, Department of Medical Sciences, University of Torino, Torino, Italy, 
2 Department of Medical Sciences, Division of Endocrinology, Diabetes and Metabolism, University of Torino, Torino, Italy, 
3 Department of Medical Sciences, Division of Oncological Endocrinology, University of Torino, Torino, Italy
Glucocorticoid receptor (GR) activation has been shown to reduce adult hippocampal 
progenitor cell proliferation and neurogenesis. By contrast, mineralocorticoid receptor 
(MR) signaling is associated with neuronal survival in the dentate gyrus of the hippocam-
pus, and impairment of hippocampal MR has been linked to pathological conditions, 
such as depression or neurodegenerative disorders. Here, we aimed to further clarify 
the protective role of MR in adult hippocampal neurons by studying the survival and 
proliferative effects of the highly potent MR agonist fludrocortisone (Fludro) in adult rat 
hippocampal progenitor cells (AHPs), along with the associated signaling mechanisms. 
Fludro, which upregulated MR but not GR expression, increased survival and prolif-
eration and prevented apoptosis in AHPs cultured in growth factor-deprived medium. 
These effects were blunted by the MR antagonist spironolactone and by high doses 
of the GR agonist dexamethasone. Moreover, they involved signaling through cAMP/
protein kinase A (PKA)/cAMP response element-binding protein, phosphoinositide 
3-kinase (PI3K)/Akt and its downstream targets glycogen synthase kinase-3β (GSK-3β) 
and mammalian target of rapamycin. Furthermore, Fludro attenuated the detrimental 
effects of amyloid-β peptide 1–42 (Aβ1–42) on cell survival, proliferation, and apoptosis 
in AHPs, and increased the phosphorylation of both PI3K/Akt and GSK-3β, which was 
reduced by Aβ1–42. Finally, Fludro blocked Aβ1–42-induced hyperphosphorylation of Tau 
protein, which is a main feature of Alzheimer’s disease. Overall, these results are the first 
to show the protective and proliferative role of Fludro in AHPs, suggesting the potential 
therapeutic importance of targeting MR for increasing hippocampal neurogenesis and 
for treating neurodegenerative diseases.
Keywords: mineralocorticoid receptor agonists, glucocorticoid receptor agonists, hippocampal progenitors, 
hippocampal progenitor cell proliferation and survival, amyloid beta peptide
Abbreviations: Aβ, amyloid-beta peptide; AD, Alzheimer’s disease; AHP, adult rat hippocampal progenitor cells; BrdU, 
5-bromo-2-deoxyuridine; BSA, bovine serum albumin; cAMP, cyclic AMP; CREB, cAMP response element-binding protein; 
DEX, dexamethasone; DMEM, Dulbecco’s Modified Eagle’s medium; ELISA, enzyme-linked immunosorbent assay; ERK1/2, 
extracellular signal-regulated protein kinases 1 and 2; FGF, fibroblast growth factor; Fludro, fludrocortisone; GSK-3β, glycogen 
synthase kinase-3 beta; IBMX, 3-isobutyl-1-methylxanthine; mTOR, mammalian target of rapamycin; MTT, 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide; NFTs, neurofibrillary tangles; NM, normal medium; p70S6K, p70 ribosomal S6 
kinase; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; RT-PCR, reverse transcriptase-polymerase chain reaction; 
Spiro, spironolactone.
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inTrODUcTiOn
The hypothalamic–pituitary–adrenal (HPA) axis is the endocrine 
center of the stress system, consisting of corticotrophin-releasing 
hormone (CRH), pituitary adrenocorticotropic hormone 
(ACTH), and adrenal corticosteroid release. At the central level, 
corticosteroids influence neuronal plasticity and excitability, 
neurogenesis and neuronal death, as well as neuroendocrine 
control and behavioral responses (1). Their actions in the brain 
are mediated by glucocorticoid receptors (GRs) and mineralocor-
ticoid receptors (MRs), which act in the cell nuclei as activators of 
gene transcription factors. MR expression is particularly high in 
the hippocampus and other limbic regions, where it co-localizes 
with GRs, which bind corticosteroid with a 10-fold lower affinity 
(3). GRs, in turn, are expressed throughout the brain, in neurons 
and glial cells, and are most abundant in hypothalamic neurons 
and corticotroph cells (2). Due to the differences in affinity, MR 
is always occupied by corticosterone, even at basal levels of HPA 
axis activity; however, higher hormone levels, after stress or 
circadian peak, progressively saturate the GR (3). Recently, rapid 
non-genomic effects have been demonstrated for MR and GR, 
which act as low-affinity membrane-associated receptor variants 
in response to rising corticosteroid levels (4).
Adult neurogenesis, which mainly occurs in the hippocampal 
subgranular zone of the dentate gyrus, is a tightly coordinated 
process involving proliferation, migration, and differentiation of 
progenitor cells. Numerous signal transduction mechanisms have 
been shown involved in hippocampal synaptic plasticity, memory 
formation, and neuronal cell proliferation and survival. These 
include cAMP/protein kinase A (PKA) and cAMP response 
element-binding protein (CREB) signaling, which play a central 
role in different steps of adult neurogenesis (5–7), and the phos-
phatidylinositol 3-kinase (PI3K)/Akt pathway, a key regulator 
of hippocampal progenitor cell proliferation and survival, also 
required for the mitogenic effects of several growth factors (8–10). 
Interestingly, PI3K/Akt was found to promote CREB phos-
phorylation, suggesting cross-talk mechanisms between these 
pathways (9). In addition, the downstream effectors of PI3K/Akt, 
glycogen synthase kinase-3β (GSK-3β) and mammalian target of 
rapamycin (mTOR) have been found involved in hippocampal 
synaptic plasticity and neuronal regeneration, and their signaling 
has been shown to be impaired in neurodegenerative disorders, 
including Alzheimer’s disease (AD) (11, 12).
Adult neurogenesis is also regulated by a variety of factors, 
including environmental factors, stress, hormones, and drugs 
(13, 14). Among the different hormones, elevation of glucocor-
ticoids or administration of exogenous glucocorticoids has been 
shown to decrease progenitor cell proliferation and hippocampal 
neurogenesis (15–21), and adrenalectomy-induced depletion of 
glucocorticoids was found to attenuate these detrimental effects 
(22). On the other hand, several studies have shown that, differ-
ently from GR, MR activation is involved in hippocampal neu-
ronal survival (4, 23). Indeed, deletion of MR in mice was found 
to reduce granule cell neurogenesis (24) and to impair learning 
ability (25), whereas MR overexpression increased differentiation 
and survival of embryonic stem (ES) cell-derived neurons (26); 
furthermore, forebrain MR overexpression enhanced memory, 
reduced anxiety, and attenuated neuronal loss in mouse cerebral 
ischemia (27). In addition, the natural MR agonist aldosterone 
was shown to counteract apoptotic hippocampal cell death 
induced by the GR agonist dexamethasone (DEX) (28) and to 
enhance neurogenesis in adrenalectomized rats (29). In humans, 
reduced MR expression and/or MR antagonism were found to be 
detrimental for the central functions and to affect HPA axis activ-
ity, suggesting that hippocampal MR, more than GR, might have 
clinical relevance in pathological conditions, such as depression, 
anxiety, or neurodegenerative diseases (30, 31).
Interestingly, different studies have shown impairment of the 
HPA axis and high glucocorticoid levels in animal models of AD 
(32, 33). Indeed, AD is an irreversible, progressive age-related 
neurodegenerative disorder that slowly destroys memory and 
thinking skills, and the hippocampus is one of the first brain 
regions to be damaged. Furthermore, it is characterized by 
accumulation of insoluble extraneuronal senile plaques, mainly 
composed of amyloid-β peptide (Aβ) and intraneuronal deposits 
of neurofibrillary tangles (NFTs), formed by hyperphosphoryl-
ated Tau protein, which cause massive neuronal death (34, 35).
Although a role for glucocorticoids and GR has been sug-
gested in the progression of AD (33), to date, the direct role of MR 
agonists on Aβ-induced toxicity has not been investigated and, 
based on the survival effects in neurons, it can be hypothesized an 
MR-induced protection against Aβ peptide-induced detrimental 
effects in hippocampal cells.
The synthetic potent and selective MR agonist fludrocortisone 
(Fludro) has been previously found to display beneficial effects on 
executive function and memory in young depressed patients, as 
well as younger and older healthy individuals (36, 37); however, its 
role on neuronal cell survival has never been assessed. Therefore, 
based on the foregoing, the present study aimed to determine 
whether Fludro exerts survival and proliferative actions in adult 
rat hippocampal progenitor cells (AHPs), in stress conditions, 
such as growth factor deprivation, and Aβ-induced toxicity. In 
addition to the MR agonist, the role of the MR selective antago-
nist spironolactone (Spiro) and of the GR agonist DEX was also 
investigated, together with the underlying signaling pathways.
MaTerials anD MeThODs
reagents
Fludrocortisone, Spiro, DEX, β-amyloid fragment (1–42), wort-
mannin, rapamycin, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT), Stemline neural stem cell medium, 
polyornithine, bovine serum albumin (BSA), and primers for 
RT-PCR were from Sigma-Aldrich (Milano, Italy). Human b-FGF, 
penicillin, streptomycin, fungizone, and trypsin were from Life 
Technologies, Inc. (Invitrogen, Milano, Italy). Quantikine immu-
noassay caspase-3 Colorimetric kit was provided by Assay Designs, 
Bologna, Italy. KT5720 was from Biomol Research Laboratory 
Inc. (DBA, Italy). Rabbit polyclonal antibodies P-Akt (Ser473), 
P-GSK-3β (Ser9), P-CREB (Ser133), and P-p70S6K (Thr389); 
mouse monoclonal antibody for P-Tau (Ser396) (PHF13) was 
from Cell Signalling Technology (Euroclone SpA, Milano, Italy). 
Total antibodies were from Abcam (Cambridge, UK). RT-PCR 
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and Real-Time PCR reagents were from Life Technologies, 
Inc. (Invitrogen, Milano, Italy). Primers for RT-PCR were from 
TibMolBiol (Genova, Italy).
cell culture and Treatments
The clonal population of AHP cells was a kind gift from Prof. 
Jorgen Isgaard (Laboratory of Experimental Endocrinology, 
Sahlgrenska Academy, University of Gothenburg, Sweden). The 
cells were isolated and cultured as previously described (10, 38). 
Briefly, AHPs were grown in polyornithine poly-coated flasks or 
wells. For normal proliferating conditions, they were cultured in 
Stemline neural stem cell medium, supplemented with 20 ng/ml 
of human b-FGF [normal medium (NM)] at 37°C in a 5% CO2 
humidified atmosphere. For experimental conditions, the cells 
were switched to Dulbecco’s Modified Eagle’s medium (DMEM)/
F12 (Sigma-Aldrich, Milano, Italy), supplemented with 0.1% BSA 
without growth factors and b-FGF for 12 h (control medium, c), 
then replaced with the same fresh medium, in either absence 
or presence of the different stimuli for further 24 h. For Aβ1–42 
treatments, AHPs were maintained in control medium for 24 h 
and after removal of the medium they were incubated for the 
indicated times with Aβ1–42 and either with or without Fludro.
cell survival and Proliferation
Cells were seeded in NM in polyornithine-coated 96-well plates at 
a cell concentration of 5 × 103 cells/well. After 48 h, the medium was 
changed to control medium and cells were treated with different 
stimuli for further 24 h. Cell survival was assessed by MTT assay. 
The cells were incubated with 1 mg/ml MTT for approximately 
1 h, then the medium was aspirated and the formazan product 
solubilized with 100 μl dimethyl sulfoxide (DMSO). Cell viability 
was assessed by spectrophotometry at 570 nm absorbance using 
the LT-4000 microplate reader (Euroclone, Milano, Italy). Cell 
proliferation was assessed using the 5-bromo-2-deoxyuridine 
(BrdU) incorporation ELISA (Roche Diagnostic SpA, Milano, 
Italy). Briefly, cells were incubated with BrdU labeling solution 
for 2 h at 37°C. After removal of the labeling solution, they were 
fixed, denatured, and incubated for 90  min with anti-BrdU 
antibody conjugate, which was subsequently removed by rinsing 
three times. Finally, the cells were incubated in substrate solution 
at room temperature and proliferation assessed by colorimetric 
detection at 450  nm absorbance using the LT-4000 microplate 
reader (Euroclone, Milano, Italy).
caspase-3 activity
Caspase-3 activity was assessed by Caspase-3 Colorimetric kit 
(Assay Designs, Bologna, Italy) in cell lysates, according to the 
manufacturer’s instruction. Caspase-3 activity was assessed by 
colorimetric detection at 450 nm absorbance using the LT-4000 
microplate reader (Euroclone, Milano, Italy).
caMP assay
Cells were seeded in NM in polyornithine-coated 6-well dishes 
at a concentration of 2 ×  105 cells. After 48  h, the medium 
was changed to control medium and the cells were incubated 
in the presence of 100  μM of 3-isobutyl-1-methylxanthine 
(IBMX) and with or without Fludro 1  μM at the indicated 
time. cAMP was measured from cell lysates using the Cyclic 
AMP Assay (R&D System, Space Srl, Milano, Italy), as previ-
ously described (10). Briefly after incubations, the medium 
was removed and the cells lysed with ice-cold 0.1 N HCl. Cell 
lysates were centrifuged for 10 min at 800 rpm, and cAMP in 
the cell lysates was measured according to the manufacturer’s 
instructions.
rT-Pcr and real-Time Pcr
Total RNA extraction from AHP cells and reverse transcrip-
tion to cDNA from 3  μg RNA were performed as previously 
described (39). Nine microliters of cDNA were amplified by 
standard polymerase chain reaction (PCR) in a 50  μl volume 
using AmpliTaq Gold Polymerase in a GeneAmp PCR System 
(Perkin Elmer, Milano, Italy) as described (10). The following 
primer pairs were used for both RT-PCR and real time PCR: 
MR (40), forward 5′-TACGACAATTCCAAGCCCGACACC-3′, 
reverse 5′-TACCTTGGCCCACTTCACGACCTG-3′ (99 bp) 
(NM_013131). GR (40), forward 5′-AGGGGAGGGGGAGCGTA 
ATGG-3, reverse 5′-CCTCTGCTGCTTGGAATCTGC-3′ (119 
bp) (AY293740); rat 18S rRNA, forward 5′-GTGGAGCGAT 
TTGTCTGGTT-3′, and reverse 5′-CGCTGAGCCAGTTCAGT 
GTA-3′(X01117). Amplification for 18S rRNA subunit was used 
as internal control. For real-time PCR, cDNA was treated with 
DNA-free DNAse (LifeTech, Monza, Italy). Real-time PCR was 
performed with 50  ng cDNA, 100  nmol/L of each primer and 
the IQ-SYBR-green mastermix (Bio-Rad, Milano, Italy) using the 
ABI-Prism 7300 (Applied Biosystems).
Western Blot analysis
Immunoblot analysis was performed as previously described 
(10, 39). Proteins (50 μg) were resolved in 11% SDS-PAGE and 
transferred to a nitrocellulose membrane; after blocking with 
1% BSA in Tris-buffered saline with 0.1% Tween for 2 h at room 
temperature, membranes were incubated overnight at 4°C with 
the specific antibody (P-CREB, P-Akt, P-GSK-3β, P-p70S6K, and 
P-Tau) (dilution 1:1000). Blots were reprobed with the respective 
total antibodies for normalization. Immunoreactive proteins 
were visualized using horseradish peroxidase-conjugated goat 
anti-mouse or goat anti-rabbit (1:5000) by enhanced chemilu-
minescence using ChemiDoc XRS (Bio-Rad, Milano, Italy) and 
densitometric analysis performed with Quantity One software 
(Bio-Rad).
statistical analysis
Data are expressed as means ± SE. Results were analyzed using 
two-tailed Student t-test or two-way ANOVA followed by Tukey 
honestly significant difference for post-ANOVA comparisons 
(GraphPad Prism 5.0 Software, San Diego, CA, USA). Significance 
was established when P < 0.05.
A B C
D E F
G H I
FigUre 2 | Fludro survival, proliferative, and antiapoptotic effects in ahPs. The cells were cultured in either normal medium (NM) or in growth factor-
deprived medium (c, control medium) for 12 h and then for further 24 h with Fludro alone, at the indicated concentrations (a–c), or with 1 μM Fludro (Flu) with or 
without either 1 μM Spiro (D–F) or 5 μM DEX (g–i). Cell survival and proliferation were assessed by MTT and BrdU incorporation assays, respectively, and apoptosis 
by caspase-3 activity. Results, expressed as percentage of control, are the mean ± SE of three independent experiments. *P < 0.05, **P < 0.01 vs. c; #P < 0.05, 
##P < 0.01; ns, not significant.
A B C
FigUre 1 | Mr and gr mrna expression in ahPs. (a) Representative images of MR and GR mRNA assessed by RT-PCR. Rat brain was used as positive 
control (c); 18S rRNA served as internal control. MR (B) and GR (c) gene expression assessed by real-time PCR in AHPs cultured in growth factor-deprived medium 
(c, control), in either absence or presence of Fludro (1 μM) for 24 h. mRNA expression was normalized to 18S rRNA and reported as fold increase vs. control. 
Results are the mean ± SEM of at least three independent experiments, each performed in duplicate. **P < 0.01 vs. c; ns, not significant.
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resUlTs
Mr and gr expression in ahP cells
MR and GR mRNAs were found expressed in AHPs, as assessed by 
RT-PCR (Figure 1A). Moreover, real-time PCR analysis showed 
that treatment with Fludro (1 μM) for 24 h strongly increased MR 
gene expression in AHPs (Figure 1B), whereas no variation was 
observed for GR (Figure 1C).
Fludro Promotes survival and Proliferation 
of ahPs and Prevents apoptosis
Once ascertained MR and GR expression, we sought to deter-
mine the biological effects induced by different concentrations 
(0.01–2 μM) of the potent synthetic MR agonist Fludro in AHPs, 
which were cultured in growth factor-deprived medium (referred 
to as control medium). As previously reported (10, 38), cell 
survival and proliferation were reduced in control, with respect 
A B
C D
FigUre 3 | involvement of caMP/PKa/creB signaling in Fludro 
survival and proliferative effects. (a) Intracellular cAMP levels in growth 
factor-deprived AHPs cultured for the indicated times with 1 μM Fludro, in the 
presence of phosphodiesterase inhibitor IBMX (100 μM), that was added 
30 min before stimulation. Forskolin (F) (50 μM for 2 min) was used as 
positive control. Results are the mean ± SE of three independent 
experiments (*P < 0.05, **P < 0.01 vs. time 0). (B) CREB phosphorylation on 
serine 133 (top panel) evaluated by Western blot in lysates from AHPs 
incubated with Fludro (1 μM) for the indicated times. Equal protein loading 
was determined by reprobing with total CREB antibody (bottom panel). Blots 
are representative of three independent experiments. Graphs show the 
densitometric analysis of phosphorylated proteins normalized to total proteins 
and reported as percentage of basal (*P < 0.05 and **P < 0.01 vs. time 0; 
ns, not significant). (c,D) Cell survival and proliferation assessed by MTT 
assay and BrdU, respectively, in AHP cells cultured in normal medium (NM) or 
in growth factor-deprived medium (c, control medium) for 12 h, and then for 
further 24 h with 0.5 μM KT5720 (KT), either alone or with 1 μM Fludro (Flu). 
Data, expressed as percentage of control, are the mean ± SE (n = 3); 
*P < 0.05, **P < 0.01 vs. c; #P < 0.05; ns, not significant.
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to growth factor-containing medium (NM) (Figures  2A,B). 
However, cell survival and proliferation progressively increased in 
AHPs treated with Fludro, with respect to NM. Fludro displayed 
these effects at the highest concentrations tested, namely from 
0.5 μM and particularly, at 1 and 2 μM (Figures 2A,B). We next 
determined the potential antiapoptotic role of the MR agonist 
and observed that, at the same concentrations, Fludro strongly 
reduced serum starvation-induced apoptosis to levels that were 
even below those of control, as assessed by reduction of caspase-3 
activity (Figure 2C). Therefore, following these results, 1 μM was 
selected as the best Fludro concentration for the subsequent 
experiments.
To next determine the involvement of MR in the effects of 
Fludro, AHPs were treated with Fludro, either alone or in com-
bination with the MR selective antagonist Spiro (41). Fludro sur-
vival, proliferative, and antiapoptotic actions were found reduced 
by cotreatment with Spiro (Figures  2D–F). Interestingly, the 
protective effects of Fludro were also abolished by high concen-
trations (5 μM) (4) of the GR agonist DEX (Figures 2G–I), which 
was previously shown to inhibit the proliferation of hippocampal 
progenitors (17, 42).
Taken together, these results suggest that Fludro elicits protec-
tive effects in AHPs, which are counteracted by either selective 
MR antagonists or high concentrations of GR agonists.
Fludro survival and Proliferative effects 
involve signaling Through caMP/Protein 
PKa and creB
Activation of the cAMP/PKA/CREB cascade plays an important 
role in the regulation of adult neurogenesis (6, 7). Furthermore, 
elevation of cAMP levels and activation of CREB by the MR agonist 
aldosterone has been previously demonstrated in porcine coro-
nary artery vascular smooth muscle cells through non-genomic 
effects (43), as well as the crosstalk between cAMP and aldosterone 
signaling in human hepatoma cell lines (44). Therefore, we next 
investigated whether Fludro-induced survival and proliferation 
would imply activation of the cAMP/PKA/CREB pathway. cAMP 
levels were found elevated by Fludro (1 μM), peaking at 15 min 
and being still significantly increased at 90  min with respect 
to untreated cells. The adenylyl cyclase activator forskolin was 
used as positive control and strongly increased cAMP levels, as 
expected (Figure 3A). Fludro also promoted the phosphoryla-
tion of CREB on serine 133, which peaked at 15 min and progres-
sively returned to basal levels at 90 min (Figure 3B). The specific 
PKA inhibitor KT5720 abolished Fludro-induced survival and 
proliferation in cells cultured in growth factor-deprived medium, 
further suggesting the involvement of PKA/CREB signaling in 
the effects of the MR agonist (Figures 3C,D).
Phosphorylation of Pi3K/akt, gsK-3β, and 
mTOr is required for Fludro survival, 
Proliferative, and antiapoptotic effects
Activation of the PI3K/Akt pathway has been shown to play 
a pivotal role in both survival and proliferation of adult hip-
pocampal progenitors, also induced by different growth factors 
(5, 9,  10). Furthermore, PI3K/Akt-mediated inactivation of 
GSK-3β through phosphorylation on Ser9 residue is crucial for 
hippocampal neurogenesis and neuronal survival (11). Here, 
Fludro-treated AHPs showed a time-dependent increase of Akt 
phosphorylation, which peaked at 30 min and decreased there-
after, although being still significantly elevated at 60 and 90 min 
compared to basal (Figure  4A). Similarly, Fludro strongly and 
time-dependently increased GSK-3β phosphorylation at Ser9, 
which was maintained up to 90 min after stimulation (Figure 4B). 
The role of Fludro was also assessed on activation of the other 
Akt effector mTOR, (12). Specifically, we studied the effect of 
Fludro on the mTOR target p70S6K and found a time-dependent 
increase of its phosphorylation at Thr389, compared to basal 
(Figure 4C). Next, to further assess the role of Akt and mTOR 
in Fludro effects, AHPs were treated with the specific inhibitors 
of these pathways. Fludro survival, proliferative, and antiapop-
totic actions were found reduced by either the Akt inhibitor 
wortmannin (Figures 4D–F) or the mTOR inhibitor rapamycin 
(Figures 4G–I), whereas these compounds alone were inactive. 
Overall, these results suggest that Fludro-induced protection 
in AHPs requires activation of PI3K/Akt and mTOR, as well as 
inactivation of GSK-3β.
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FigUre 4 | involvement of Pi3K/akt, gsK-3β, and mTOr/p70s6K signaling in Fludro effects. (a) Akt, (B) GSK-3β, and (c) p70S6K phosphorylation 
evaluated by Western blot in AHPs treated with 1 μM Fludro for the indicated times (upper panels). Blots, each representative of three independent experiments, 
were reprobed with total antibodies for normalization (lower panels). Graphs show phosphorylated proteins normalized to total proteins and reported as percentage 
of basal (*P < 0.05 and **P < 0.01 vs. time 0). (D–i) Cell survival, proliferation, and apoptosis assessed by MTT, BrdU, and caspase-3 activity, respectively, in AHPs 
cultured in normal medium (NM) or in growth factor-deprived medium (c, control medium) for 12 h, and then for further 24 h with either wortmannin (Wort, 100 nM) 
(D–F) or rapamycin (Rap, 50 nM) (g–i), both alone or with 1 μM Fludro (Flu). Data, expressed as percentage of c, are the mean ± SE of four independent 
experiments. *P < 0.05, **P < 0.01 vs. c; #P < 0.05; ns, not significant.
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Fludro counteracts the Detrimental 
effects of aβ Peptide 1–42
Aβ peptides exert toxic effects in a variety of neural cell types by 
reducing survival and proliferation. Indeed, abnormal Aβ peptide 
1–42 (Aβ1–42) deposition is one of the main hallmarks of AD and 
contributes to neuronal apoptotic cell death in the hippocampus 
and cerebral cortex. Moreover, Aβ1–42 plays a critical role in the 
hyperphosphorylation of Tau protein and the consequent forma-
tion of NFTs (34, 35). Fludro-induced survival and proliferative 
effects observed in growth factor-deprived conditions led us to 
hypothesize a protective role of the MR agonist against Aβ1–42-
induced cell death. In AHPs treated for 24 h with 1 μM Aβ1–42, 
whose concentration was selected on the basis of our previous 
findings (10), coincubation with Fludro attenuated the detrimen-
tal effect of the peptide by increasing survival and proliferation and 
restoring apoptosis to control levels (Figures 5A–C). Consistent 
with the previous results, Fludro, which per se promoted both Akt 
and GSK-3β phosphorylation, also counteracted Aβ1–42-induced 
reduction of Akt and GSK-3β phosphorylation (Figures 5D,E). 
Next, the effect of Fludro was examined on Tau protein, whose 
hyperphosphorylation by GSK-3β is involved in the formation 
of NFTs and the pathogenesis of AD (35, 45). Figure 5F shows 
that Fludro alone had no effect with respect to control; however, 
it completely blocked Aβ1–42-induced phosphorylation of Tau. 
Collectively, these findings suggest a protective role for Fludro 
against Aβ1–42-induced toxicity in hippocampal progenitors.
DiscUssiOn
This study is the first to describe the survival, proliferative, 
and antiapoptotic effects of the MR agonist Fludro in adult rat 
hippocampal progenitors. Fludro counteracted the detrimental 
effects of growth factor deprivation through mechanisms involv-
ing activation of the cAMP/PKA/CREB signaling and PI3K/
Akt and mTOR pathways, as well as inactivation of GSK-3β. 
Furthermore, Fludro reduced the negative effects of Aβ1–42 on 
AHP survival, proliferation, and apoptosis through Akt and 
GSK-3β-mediated signaling and inhibition of Aβ1–42-induced 
hyperphosphorylation of Tau protein.
Adult hippocampal neurogenesis comprises proliferation and 
differentiation of progenitors, survival and maturation of new 
neurons, and their integration into neuronal circuits. Defects in 
A B C
D E F
FigUre 5 | survival effects of Fludro against aβ1–42-induced toxicity in ahPs. (a–c) Cell survival, proliferation, and apoptosis in cells treated for 24 h in 
control medium (c) with or without Aβ1–42 (1 μM) and in either absence or presence of Fludro (1 μM). Data, expressed as percentage of c, are the mean ± SE of four 
replicates. *P < 0.05 and **P < 0.01 vs. c; #P < 0.05 and ##P < 0.01; ns, not significant. (D) Akt, (e) GSK-3β, and (F) Tau phosphorylation (top panels) assessed by 
Western blot in cells treated with Aβ1–42 (1 μM) and Fludro (1 μM), either alone or in combination. The cells were pretreated with Fludro for 30 min and then treated 
with Aβ1–42 for 60 min. Blots were reprobed with total antibodies for normalization (lower panels). Graphs show phosphorylated proteins normalized to total proteins 
and reported as percentage of basal. *P < 0.05 and **P < 0.01 vs. c; #P < 0.05 and ##P < 0.01; ns, not significant (n = 3).
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neurogenesis cause memory impairment and cognitive deficits 
and have been found to be critical events in aging and neuro-
degenerative diseases, including AD (13, 14). Both MR and GR 
are abundantly expressed in the limbic areas, where they display 
quite opposite effects (1, 2). Indeed, MRs play an essential role 
in the neuroendocrine and behavioral responses to stress and 
in cognitive functions, and are involved in the integrity and 
stability of neuronal networks (4, 23). On the other hand, activa-
tion of GR by high levels of glucocorticoids promotes neuronal 
death through cell cycle arrest and induction of apoptosis 
(17, 20, 21, 46). We show here expression of both MR and GR 
in AHPs and interestingly, MR, but not GR, mRNA expression 
was found increased by treatment with Fludro, suggesting a 
specific role for MR in mediating Fludro survival and prolif-
erative effects. This assumption was also bolstered by the results 
showing that the MR antagonist Spiro was able to counteract the 
actions of Fludro in AHPs. Furthermore, previous studies have 
demonstrated that MR overexpression in  vitro was associated 
with increased survival of rat primary cortical neurons, as well 
as neuroprotection in rat hippocampus and decreased sensitiv-
ity to stress (47). In addition, exposure to chronic stressors was 
previously found to downregulate hippocampal MR, leading to 
a reduced MR:GR ratio, and decreased hippocampal MRs have 
been associated with enhanced stress-induced HPA axis activity 
(48). Interestingly, antidepressant administration increased MR 
expression (49); furthermore mice with conditional forebrain-
specific MR overexpression showed an attenuated HPA axis 
response to stress (50) and MR overexpression was recently 
shown to confer resilience to the effects of chronic stress on 
hippocampus-dependent function and structural plasticity (51). 
Moreover, murine ES cells that overexpressed human MR and 
were induced to differentiate into mature neurons showed 
increased neuron survival and increased ratio of anti- vs. proa-
poptotic molecules (26). Therefore, in our study increased MR 
expression may be a mechanism whereby Fludro promotes cell 
survival and counteracts apoptosis induced by growth factor 
deprivation.
Although the neuroprotective actions of MR and of natural MR 
agonists, such as aldosterone have been described (4, 23, 26–28), 
to the best of our knowledge, this is the first study showing the 
protective role of Fludro in hippocampal progenitors. We and 
others have recently reported that high doses of Fludro display 
inhibitory effects on the HPA axis in humans, likely through 
binding to hippocampal MR (52–54), whereas MR antagonism 
increased HPA axis activity (31). Accordingly, Fludro also 
enhanced efficacy of antidepressants and improved memory and 
executive functions in young depressed patients (48). These find-
ings led us to hypothesize that the highly selective MR agonist 
Fludro, similarly to the natural agonist aldosterone, would display 
protective action in adult hippocampal progenitors. Indeed, we 
show here that Fludro counteracted the effects of growth factor 
deprivation in AHPs by promoting cell survival and proliferation, 
and reducing apoptosis. To date, very few studies have described 
the effects of Fludro on cells; among these, Fludro was found to 
stimulated cell viability in bladder cancer cell lines (55), whereas 
in neurons, it increased nerve growth factor (NGF)-induced 
neurite outgrowth in a neuronal model derived from PC12 
pheochromocytoma line (56). Conversely, at variance with 
the previously observed survival actions of MR, a recent study 
demonstrated Fludro-induced neuron damage in pyramidal cells 
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of the hippocampal CA3 region, which expressed only MR and 
not GR (57).
Herein, we show that the survival effects of Fludro in AHPs 
were attenuated not only by the MR antagonist Spiro, suggest-
ing MR specificity, but also by the GR agonist DEX. In fact, as 
previously demonstrated in hippocampal cells (17), DEX alone 
strongly reduced cell survival and proliferation in growth factor-
deprived AHPs, whereas it had no effect on apoptosis. Fludro was 
likely unable to counteract such a strong death response to GR 
activation; in addition, DEX also reduced the antiapoptotic effect 
of Fludro, although having no proapoptotic effect on its own. 
These results suggest that upon stress conditions, such as high 
DEX levels, MR response is unable to attenuate the detrimental 
effects of GR.
The limitation of the present study is that the experiments have 
been performed using a single cell type. However, the adult rat 
hippocampus-derived progenitors, employed herein, were origi-
nally isolated from the rat hippocampal dentate gyrus and are a 
well-established cell model, which have been thoroughly studied 
with regard to their proliferative capacities and lineage stability. 
Most importantly, they can generate the three main lineages of 
the central nervous system (8, 38, 58).
In addition to the classical long-lasting genomic mecha-
nisms regulating gene transcription, MRs have been recently 
shown to influence cellular physiology through rapid non-
genomic pathways (59). These are represented by low-affinity 
membrane receptors that are activated when corticosteroid 
levels rise, for example, shortly after stress exposure, and are 
most likely located on the presynaptic terminal in hippocam-
pal neurons; moreover, their effects were found to be blocked 
by Spiro (4, 60). Furthermore, aldosterone has been shown to 
induce a rapid increase of cAMP levels and to promote CREB 
phosphorylation in vascular smooth muscle cells through 
non-genomic mechanisms; in this study, however, these effects 
were not blocked by the MR antagonist Spiro or by inhibitors 
of transcription and protein synthesis (43). Moreover, cAMP 
potentiated the activation of transcription by aldosterone of a 
GRE-containing promoter in different cell types (44). In line 
with these studies, we show here that Fludro rapidly increased 
cAMP in AHPs and also promoted the phosphorylation 
of CREB, suggesting activation of non-genomic pathways. 
Furthermore, Fludro-induced survival and proliferation was 
reduced by the PKA inhibitor KT5720, further supporting 
the implication of cAMP/PKA/CREB signaling, which is 
recognized as a central player in different steps of adult neuro-
genesis, including hippocampal cell survival, maturation, and 
integration of new neurons (6, 7).
Recently, rapid non-genomic effects of glucocorticoids were 
also observed in hippocampal neurons, where corticosterone 
promoted the activation of both PKA and PI3K/Akt (61); however, 
the role of MR on activation of survival signaling pathways is still 
quite unknown. Furthermore, the importance of PI3K/Akt activ-
ity on proliferation and survival of adult hippocampal progenitors 
(8, 9), as well as its association with CREB phosphorylation, has 
been previously described (9). Interestingly, we show here rapid 
Fludro-induced phosphorylation of Akt in AHPs; moreover, Akt 
inhibition by wortmannin reduced Fludro survival, proliferative, 
and antiapoptotic effects. Similarly, Fludro rapidly increased the 
phosphorylation of the PI3K/Akt downstream targets GSK-3β 
and mTOR/p70S6K, which resulted in their inactivation and 
activation, respectively. GSK-3β, a key component of the Wnt 
pathway, plays a crucial role in progenitor cell differentiation 
and survival during neurogenesis, as well as in neuronal survival 
(11). Furthermore, impaired GSK-3β activity has been associ-
ated with psychiatric disorders and neurodegenerative diseases, 
including AD (45). Interestingly, as for Akt, Fludro survival and 
mitogenic actions were reduced in the presence of the mTOR 
inhibitor rapamycin, suggesting rapamycin sensitive mTOR 
complex 1 (mTORC1)-mediated mechanisms. Accordingly, 
mTOR/p70S6K pathway has been linked to synaptic plasticity 
and neurogenesis, and mTOR signaling impairment has been 
related to neurodegenerative disorders, including autism and AD 
(12). Therefore, on the basis of the protective effects observed in 
growth factor-deprived conditions and the signaling pathways 
involved, we next sought to determine whether Fludro would 
protect AHPs from the detrimental effects of Aβ1–42 peptide. 
Indeed, Aβ1–42 is a main responsible for neuronal death, memory, 
and cognitive impairment in AD (34, 35). Furthermore, different 
studies have described the correlation between high glucocorti-
coid levels or dysregulation in the corticosteroid system and AD 
(32, 33). In fact, in both in vitro and in vivo models, stress-levels 
of glucocorticoids were found to increase Aβ formation and 
Tau accumulation, through GR-mediated mechanisms (62). 
Moreover, elevated glucocorticoid levels increased susceptibility 
of cholinergic neurons to Aβ1–42-mediated toxicity in  vivo (63) 
and in hippocampal neuronal cultures (64). Conversely, CRH, 
which initiates neuroendocrine responses to stress by activat-
ing the HPA axis, was found to reduce cell death caused by an 
Aβ peptide in primary hippocampal and cortical neurons, an 
effect that was blocked by a CRH receptor antagonist and by an 
inhibitor of PKA (65). However, so far the direct effect of MR 
agonists on Aβ-induced toxicity in hippocampal cells has never 
been investigated. Here, we show for the first time that Fludro 
counteracts the detrimental effects of Aβ1–42 in AHPs, by increas-
ing cell survival and proliferation and reducing apoptosis. Fludro 
also increased both Akt and GSK-3β phosphorylation, that was 
reduced by Aβ1–42, and restored Aβ1–42-induced phosphorylation 
of Tau to basal levels.
Overall, these findings are the first to show the protective and 
proliferative role of Fludro in adult hippocampal progenitors 
exposed to different stress stimuli, including those characteristics 
of neurodegenerative diseases. These effects likely involved both 
genomic and non-genomic mechanisms, as suggested by the 
activation of specific signaling pathways. Therefore, the results of 
this study further support the previously observed neuroprotec-
tive role of MR and suggest that MR agonists may represent a 
possible therapeutic strategy for reducing hippocampal cell loss, 
improving neurogenesis and for approaching neurodegenerative 
diseases, such as AD.
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